Recognizing that our traditional models to pandemic preparedness have failed to imagine the risk and broad societal impact of biological threats, McMaster University sought support to establish a new way forward.
A top-5 pharmaceutical company sought to understand differentiating features of competitor COVID-19 vaccine programs and forecast regional market scenarios and commercial implications.
CIHR’s Institute of Infection & Immunity (III) engaged Shift Health to support the development of a 5-year strategic plan that reflected the research interests and strengths of Canada’s infection and immunity research community and the implications of the COVID-19 pandemic.
With an urgent need to integrate and improve public health efforts across the Gulf region—an imperative amplified by the COVID-19 pandemic—the Gulf Health Council (GHC) engaged Shift Health to develop a foundational strategic, operating and implementation plan for the Gulf Centre for Disease Control and Prevention.
Uncovering Lifecycle Management Options to Maximize the Value of a Novel Antiviral Beyond Treatment of COVID-19
A global pharmaceutical giant engaged Shift Health to explore additional RNA virus indications to inform lifecycle management for a promising antiviral in clinical development for COVID-19.
A global health consortium required support in attracting greater industry investment into the traditionally underfunded area of Strep A vaccine development.
The Saudi government sought to establish a national public health agency as a critical component of its efforts to transform the country’s entire health system.
In the face of constrained R&D budgets, a top-5 pharmaceutical company needed support to develop a transformative, corporate-wide strategy to assess and secure external funding.
The Alzheimer Society of Canada—the national body of a federation of dozens of provincial societies and regional chapters—needed a strategy to deliver a newly-approved mandate.